Journal of Chemotherapy

Papers
(The H4-Index of Journal of Chemotherapy is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Ceftobiprole and daptomycin concentrations in valve tissue in a patient with mitralic native valve endocarditis51
Clinical evaluation of camrelizumab combined with transarterial chemoembolization in the interventional therapy of hepatocellular carcinoma with liver cirrhosis38
Comparative effectiveness of chemotherapy in different histological types of pancreatic cancer: a PSM-based study using the SEER database30
Comparative in vitro activities of eravacycline in combination with colistin, meropenem, or ceftazidime against various Achromobacter spp. strains isolated from patients with cystic fibrosis25
Innovative sequential therapy in a rare case of refractory Erdheim-Chester disease with bilateral pulmonary involvement24
Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients20
Looking for Stenotrophomonas maltophilia treatment: in vitro activity of ceftazidime/avibactam alone and in combination with aztreonam18
Efficacy and safety of intravenous fosfomycin for the treatment of carbapenem-resistant Klebsiella pneumoniae15
Nivolumab-induced Lambert-Eaton myasthenic syndrome: an immune-related adverse event in nonsmall cell lung cancer14
YAP/TAZ axis was involved in the effects of metformin on breast cancer13
Enzalutamide combination with Arsenic trioxide suppresses the progression of castration-resistant prostate cancer13
Reevaluating immunotherapy’s potential in first-line metastatic urothelial carcinoma12
MiR-302a-3p reduces cisplatin resistance of esophageal squamous cell carcinoma cells by targeting EphA212
Optimization of the vancomycin administration regimen by clinical pharmacists based on a population pharmacokinetics model: a prospective interventional study12
Piperacillin/Tazobactam is associated with a higher risk of acute kidney injury compared to cefepime and meropenem12
0.44594502449036